Top Story

Drawings assess patient perceptions after remission of acromegaly

March 2, 2015

A drawing test could be a relatively easy way for clinicians to assess patient perceptions after long-term remission from acromegaly, according to research published in the European Journal of Endocrinology.

“Patients are labeled ‘cured’ by medical doctors but still feel like a patient with acromegaly,” Jitske Tiemensma, PhD, of the University of California, Merced, said in a news release. “It might be difficult for a patient to bring up lingering physical symptoms, and medical doctors might not always recognize what’s going on.”

In the Journals

Energetic adaptations persist in adolescents with extreme obesity after Roux-en-Y

February 27, 2015
Adolescents with extreme obesity who underwent Roux-en-Y gastric bypass experienced energetic adaptations that favor weight regain, along with changes in insulin…
In the Journals

Napping could reverse health consequences of sleep debt

February 10, 2015
Taking naps appears to release stress and deliver positive effects on immune responses, according to research published in The Journal of Clinical Endocrinology &
In the Journals

Oral octreotide safe, effective as monotherapy for acromegaly in phase 3 trial

February 10, 2015
An oral therapeutic peptide helped patients with acromegaly control insulin-like growth factor-1 and growth hormone for up to 13 months after they switched from…
CME
low no

Low- and No-Calorie Sweeteners in Weight Management: What Do You Need to Know?

This activity is supported by an educational grant from the American Beverage Association.

The use of low- and no-calorie sweeteners continues to grow as consumers continue to purchase foods and beverages…
More »
Obesity Consults

Obesity Consults: Volume 2, Number 5
Practical Guide to Medications Approved for Chronic Weight Management

Several pharmacologic options for the management of obesity have been approved by the US FDA, giving clinicians a range…
More »
In the Journals

Drawings assess patient perceptions after remission of acromegaly

March 2, 2015
A drawing test could be a relatively easy way for clinicians to assess patient perceptions after long-term remission from acromegaly, according to…
In the Journals

Energetic adaptations persist in adolescents with extreme obesity after Roux-en-Y

February 27, 2015
Adolescents with extreme obesity who underwent Roux-en-Y gastric bypass experienced energetic adaptations that favor weight regain, along with…
In the Journals

Napping could reverse health consequences of sleep debt

February 10, 2015
Taking naps appears to release stress and deliver positive effects on immune responses, according to research published in The Journal of Clinical
In the Journals

Oral octreotide safe, effective as monotherapy for acromegaly in phase 3 trial

February 10, 2015
An oral therapeutic peptide helped patients with acromegaly control insulin-like growth factor-1 and growth hormone for up to 13 months after they…
Alexandria Phan Meeting News Coverage

Lanreotide shows promise in patients with pancreatic neuroendocrine tumors

January 28, 2015
Lanreotide demonstrated antitumor activity with a manageable safety profile in patients with pancreatic neuroendocrine tumors, according to a…
Daniel Kaemmerer In the Journals

Somatostatin receptors serve as viable markers in bronchopulmonary neuroendocrine neoplasms

January 23, 2015
Somatostatin receptors may have utility as diagnostic, prognostic and therapeutic markers of bronchopulmonary neuroendocrine neoplasms, according to…
In the Journals

Temsirolimus, bevacizumab shows promise for pancreatic neuroendocrine tumors

January 22, 2015
Combination treatment with temsirolimus and bevacizumab demonstrated considerable activity and a reasonable safety profile in patients with…
Kate Nathanson In the Journals

ATRX mutation possible biomarker for rare neuroendocrine tumors

January 22, 2015
A somatic mutation in the ATP-dependent helicase, or ATRX,  gene — recently demonstrating potential as a molecular marker for…

Versartis Inc. reports long-acting recombinant growth hormone extension trial data

January 11, 2015
The 12-month results from an extension study looking at long-term safety and efficacy of a novel, long-acting form of recombinant human growth…
FDA approvals

FDA approves Somatuline Depot for gastroenteropancreatic neuroendocrine tumors

December 16, 2014
The FDA today approved lanreotide for treatment of patients with unresectable, well- or moderately differentiated, locally advanced or metastatic…
More Headlines »
morganatic-roan
morganatic-roan